Betahistine mesylateProduct ingredient for Betahistine
- Name
- Betahistine mesylate
- Drug Entry
- Betahistine
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.2,13
Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to reduce symptoms through its actions on histamine receptors.4,12 Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.
- Accession Number
- DBSALT002969
- Structure
Structure for Betahistine mesylate (DBSALT002969)
- Synonyms
- Betahistine dimesilate / Betahistine dimesylate / Betahistine mesilate / Betahistine mesylate
- UNII
- X1L0E3R43Y
- CAS Number
- 54856-23-4
- Weight
- Average: 328.4
Monoisotopic: 328.07627872 - Chemical Formula
- C10H20N2O6S2
- InChI Key
- ZBJJDYGJCNTNTH-UHFFFAOYSA-N
- InChI
- InChI=1S/C8H12N2.2CH4O3S/c1-9-7-5-8-4-2-3-6-10-8;2*1-5(2,3)4/h2-4,6,9H,5,7H2,1H3;2*1H3,(H,2,3,4)
- IUPAC Name
- bis(methanesulfonic acid); methyl[2-(pyridin-2-yl)ethyl]amine
- SMILES
- CS(O)(=O)=O.CS(O)(=O)=O.CNCCC1=CC=CC=N1
- External Links
- Predicted Properties
Property Value Source Water Solubility 49.3 mg/mL ALOGPS logP 0.59 ALOGPS logP 0.63 Chemaxon logS -0.44 ALOGPS pKa (Strongest Basic) 9.77 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 24.92 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 41.33 m3·mol-1 Chemaxon Polarizability 15.85 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon